5-(N,N-dimethyl)-Amiloride (hydrochloride): Selective NHE Inhibitor for pH and Ion Transport Research

Executive Summary. 5-(N,N-dimethyl)-Amiloride (hydrochloride) (DMA) is a crystalline inhibitor of Na+/H+ exchanger isoforms NHE1, NHE2, and NHE3, with Ki values of 0.02, 0.25, and 14 μM, respectively, under physiological buffer conditions at 25°C [APExBIO]. Selectivity for these isoforms with minimal NHE4, NHE5, and NHE7 inhibition allows precise study of intracellular pH regulation and sodium transport in mammalian cells [Chen et al. 2021, DOI]. DMA demonstrates protective effects against cardiac ischemia-reperfusion injury by normalizing sodium levels and preventing contractile dysfunction in preclinical models. The compound is soluble up to 30 mg/ml in DMSO or DMF and is available as the C3505 kit from APExBIO, intended for research use only [APExBIO]. DMA also inhibits ouabain-sensitive ATP hydrolysis and sodium-potassium ATPase activity in rat liver plasma membranes, highlighting broader effects on ion transport and metabolism.

Biological Rationale

Regulation of intracellular pH and sodium ion concentration is critical for cell survival, function, and response to stress. The Na+/H+ exchangers (NHEs), especially NHE1, NHE2, and NHE3, mediate proton extrusion and sodium uptake in most mammalian cells, maintaining pH homeostasis and cell volume [Chen et al. 2021]. Disruption of these pathways contributes to pathologies such as ischemia-reperfusion injury, cardiac contractile dysfunction, and sepsis-related endothelial damage. Selective pharmacological inhibition of NHE isoforms enables precise dissection of these mechanisms in disease models. 5-(N,N-dimethyl)-Amiloride (hydrochloride) offers a validated tool for this purpose, improving on the specificity and solubility profiles of earlier amiloride analogs [Benchmark NHE Article]. This article updates previous reviews by specifically detailing DMA's selectivity parameters and workflow integration.

Mechanism of Action of 5-(N,N-dimethyl)-Amiloride (hydrochloride)

DMA inhibits Na+/H+ exchanger activity by reversibly binding to the transporter at the extracellular face, preventing the exchange of intracellular H+ for extracellular Na+. This leads to intracellular acidification and reduced sodium influx, disrupting pH recovery after acid load. The compound exhibits Ki values of 0.02 μM for NHE1, 0.25 μM for NHE2, and 14 μM for NHE3 under standard in vitro assay conditions (pH 7.4, 25°C) [Selective NHE1 Inhibitor Article]. Minimal inhibitory activity is observed for NHE4, NHE5, and NHE7. In addition to NHE inhibition, DMA attenuates ouabain-sensitive ATPase activity and alanine uptake in hepatocytes, further impacting cellular ion homeostasis. In endothelial and cardiac models, this mechanism reduces sodium overload and mitigates contractile dysfunction during ischemia-reperfusion injury [Chen et al. 2021].

Evidence & Benchmarks

• DMA inhibits NHE1 with a Ki of 0.02 μM, NHE2 at 0.25 μM, and NHE3 at 14 μM in mammalian cell assays (buffered at pH 7.4, 25°C) (APExBIO).
• DMA displays minimal inhibition of NHE4, NHE5, and NHE7, providing isoform selectivity for research on specific sodium-proton exchange pathways (Selective NHE1 Inhibitor Article).
• DMA administration in cardiac ischemia-reperfusion models normalizes tissue sodium and improves contractile function, suggesting protective roles in acute injury (Chen et al. 2021, DOI).
• In rat liver plasma membranes, DMA inhibits ouabain-sensitive Na+/K+-ATPase activity and ATP hydrolysis at 10–50 μM, affecting sodium and metabolic fluxes (APExBIO).
• DMA reduces alanine uptake in hepatocytes by modulating sodium-coupled transporter activity, with maximal inhibition at 50 μM (APExBIO).

While previous summaries highlight the compound's role in cardiovascular research, this article focuses on quantitative selectivity data and workflow integration for advanced users. For a broader translational perspective on endothelial biomarker research, see this companion article, which is extended here by explicit linkage to NHE isoform-specific parameters and solubility profiles.

Applications, Limits & Misconceptions

Research Applications:

• Cardiovascular disease modeling and ischemia-reperfusion injury research via selective NHE1/NHE2/NHE3 inhibition.
• Cell volume regulation and intracellular pH homeostasis assays in mammalian cells.
• Dissection of sodium transport and energy metabolism in hepatocytes and endothelial cells.
• Screening for cytoprotective interventions in endothelial injury models, particularly in sepsis and acute inflammation [Chen et al. 2021].

Common Pitfalls or Misconceptions

• DMA is not recommended for long-term solution storage; activity declines significantly after freeze-thaw or >24 hours at room temperature.
• DMA does not inhibit NHE isoforms 4, 5, or 7 at concentrations ≤50 μM; it is unsuitable for studies requiring pan-NHE blockade.
• DMA is not appropriate for diagnostic or therapeutic use—research applications only (research use only, not for medical use).
• DMA is ineffective in non-mammalian systems lacking homologous NHE isoforms.
• Over-interpretation of metabolic effects beyond direct NHE and ATPase inhibition should be avoided without orthogonal validation.

This article clarifies solubility parameters and workflow best practices, which were only briefly mentioned in prior reviews.

Workflow Integration & Parameters

• Solubility: DMA is soluble up to 30 mg/ml in DMSO or dimethyl formamide (DMF). Prepare solutions fresh for each experiment to ensure maximal activity [APExBIO].
• Storage: Store powder at -20°C; avoid repeated freeze-thaw cycles of solutions.
• Concentration Range: Use at 0.01–50 μM for cell-based assays, with isoform selectivity at ≤1 μM for NHE1/NHE2.
• Experimental Controls: Include vehicle controls (DMSO or DMF only) and pH-matched buffers to isolate NHE-specific effects.
• Time Course: Incubate cells for 5–60 minutes, depending on endpoint; monitor intracellular pH and sodium using validated fluorometric or ion-sensitive probes.
• Documentation: Report batch number, solvent, and storage conditions for reproducibility.

For a comprehensive discussion of NHE pathway modeling and emerging biomarker integration, this article is complemented here by explicit solubility and workflow benchmarks.

Conclusion & Outlook

5-(N,N-dimethyl)-Amiloride (hydrochloride) is a validated, selective Na+/H+ exchanger inhibitor for research on intracellular pH regulation, sodium transport, and cardiovascular injury mechanisms. Its high selectivity for NHE1/NHE2/NHE3, favorable solubility, and compatibility with standard cell and tissue models position it as a benchmark reagent for both mechanistic and translational studies. The C3505 kit from APExBIO enables rigorous, reproducible experimental workflows. Future research may further leverage DMA in conjunction with emerging endothelial biomarkers, such as moesin, to refine disease models and intervention strategies [Chen et al. 2021, DOI]. For product details and ordering, consult the official APExBIO product page.